X4 Pharmaceuticals (XFOR) announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities are being offered by X4. X4 intends to use the net proceeds from this offering to fund the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders, as well as for general and administrative expenses, capital expenditures, working capital and other general corporate purposes. Leerink Partners, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XFOR:
- Altimmune appoints Christophe Arbet-Engels as CMO
- X4 Pharmaceuticals Announces Major Strategic Restructuring
- X4 Pharmaceuticals announces restructuring, 50% reduction in workforce
- X4 Pharmaceuticals files to sell 59.89M shares of common stock for holders
- X4 Pharmaceuticals price target lowered to $9 from $30 at Stifel